1. Home
  2. Publications
  3. Clonal somatic copy number altered driver...

Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer

Abstract:
Chromosomal instability is a major challenge to patient stratification and targeted drug development for high-grade serous ovarian carcinoma (HGSOC). Here we show that somatic copy number alterations (SCNAs) in frequently amplified HGSOC cancer genes significantly correlate with gene expression and methylation status. We identify five prevalent clonal driver SCNAs (chromosomal amplifications encompassing MYC, PIK3CA, CCNE1, KRAS and TERT) from multi-regional HGSOC data and reason that their strong selection should prioritise them as key biomarkers for targeted therapies. We use primary HGSOC spheroid models to test interactions between in vitro targeted therapy and SCNAs. MYC chromosomal copy number is associated with in-vitro and clinical response to paclitaxel and in-vitro response to mTORC1/2 inhibition. Activation of the mTOR survival pathway in the context of MYC-amplified HGSOC is statistically associated with increased prevalence of SCNAs in genes from the PI3K pathway. Co-occurrence of amplifications in MYC and genes from the PI3K pathway is independently observed in squamous lung cancer and triple negative breast cancer. In this work, we show that identifying co-occurrence of clonal driver SCNA genes could be used to tailor therapeutics for precision medicine.
Authors:
FC Martins, D-L Couturier, I de Santiago, CM Sauer, M Vias, M Angelova, D Sanders, A Piskorz, J Hall, K Hosking, A Amirthanayagam, S Cosulich, L Carnevalli, B Davies, TBK Watkins, IG Funingana, H Bolton, K Haldar, J Latimer, P Baldwin, R Crawford, M Eldridge, B Basu, M Jimenez-Linan, AW Mcpherson, N McGranahan, K Litchfield, SP Shah, I McNeish, C Caldas, G Evan, C Swanton, JD Brenton
Journal:
Nat Commun
Citation info:
13(1):6360
Publication date:
26th Oct 2022
Full text
DOI